Palmetto Targets AstraZeneca’s Crestor In IP Suit

Law360, New York (April 5, 2011, 3:46 PM EDT) -- Palmetto Pharmaceuticals LLC  launched a suit Tuesday in South Carolina alleging AstraZeneca Pharmaceuticals LP’s blockbuster cholesterol-lowering drug Crestor infringes Palmetto’s patent.

The Charleston, S.C.-based drugmaker filed its complaint in the U.S. District Court for the District of South Carolina, taking issue with AstraZeneca’s manufacture and sale of Crestor. Palmetto’s patent, U.S. Patent Number 6,465,516, covers a method of stimulating nitric oxide synthase and was issued in October 2002. A re-examination certificate was issued this month.

AstraZeneca’s Crestor is an Hmg-CoA reductase inhibitor, used to treat individuals...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.